Other formats:
BibTeX
LaTeX
RIS
@article{1484536,
author = {Vrablik, Michal and Raslova, Katarina and Vohnout, Branislav and Blaha, Vladimir and Satny, Martin and Kyselák, Ondřej and Vaclova, Martina and Urbanek, Robin and Maskova, Jana and Soška, Vladimír and Freiberger, Tomáš},
article_location = {Clare},
article_number = {OCT 2018},
doi = {http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008},
keywords = {Familial hypercholesterolemia; LDL-C goal attainment; Treatment pattern; LDL-Cholesterol; Statins; Ezetimibe},
language = {eng},
issn = {0021-9150},
journal = {Atherosclerosis},
title = {Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry},
volume = {277},
year = {2018}
}
TY - JOUR
ID - 1484536
AU - Vrablik, Michal - Raslova, Katarina - Vohnout, Branislav - Blaha, Vladimir - Satny, Martin - Kyselák, Ondřej - Vaclova, Martina - Urbanek, Robin - Maskova, Jana - Soška, Vladimír - Freiberger, Tomáš
PY - 2018
TI - Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
JF - Atherosclerosis
VL - 277
IS - OCT 2018
SP - 355-361
EP - 355-361
PB - ELSEVIER SCI IRELAND LTD
SN - 00219150
KW - Familial hypercholesterolemia
KW - LDL-C goal attainment
KW - Treatment pattern
KW - LDL-Cholesterol
KW - Statins
KW - Ezetimibe
N2 - Background and aims: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. Methods: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. Results: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p= 0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. Conclusions: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.
ER -
VRABLIK, Michal, Katarina RASLOVA, Branislav VOHNOUT, Vladimir BLAHA, Martin SATNY, Ondřej KYSELÁK, Martina VACLOVA, Robin URBANEK, Jana MASKOVA, Vladimír SOŠKA and Tomáš FREIBERGER. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. \textit{Atherosclerosis}. Clare: ELSEVIER SCI IRELAND LTD, 2018, vol.~277, OCT 2018, p.~355-361. ISSN~0021-9150. Available from: https://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008.
|
